• RevImmune Advances New COVID-19 Immunotherapy americanpharmaceuticalreview
    November 04, 2020
    RevImmune announced its "ILIAD-7" international randomized controlled Phase 2 trial in patients critically ill with COVID-19, is now enrolling patients at five sites in the U.S.
PharmaSources Customer Service